Pneumococcus

Pneumococcus
For Japanese Investigators only. Regional AOI included.
The following areas are of interest to Merck Investigator Studies Program Committee:
Global AOI
• Development and/or assessment of non-invasive diagnostic methods to reliably
identify pneumococcal serotypes causing disease, with particular focus on
non-bacteremic pneumonia in adults, and acute otitis media and pneumonia in
infants.
o Pathogenesis: Studies in a suitable animal model to investigate the factors
associated with the pathogenesis of pneumococcal disease (invasive and
noninvasive) in the setting of pneumococcal carriage. Identification of
pneumococcal molecular determinants associated with pneumococcal
disease in the context of co-infection with other viral or bacterial pathogens
as well as other conditions associated with increased risk for pneumococcal
disease.
• In vitro or modest (small scale) nonhuman primate studies investigating the role of
plasma cells and /or memory B cells (other than from peripheral blood) for the
efficacy of pneumococcal polysaccharide or conjugate vaccines.
• Small-scale studies to evaluate the role of novel delivery devices to enhance the
immunogenicity of pneumococcal vaccines in adults.
Regional AOI for Japan
• Real world effectiveness studies that assess population impact after a PPV23
routine immunization program
• Studies that include sequential dosing of PCV13 and PPV23 that evaluate
immunoglobulin G(IgG), and opsonophagocytic activity
• Studies evaluating the immunogenicity and safety of concomitant vaccination of
PPV23 and influenza vaccines
Merck Investigator Studies Programsサイト（クリックすると、Merck & Co., Incが運営する米国MISP
ウェブサイトのAOI情報へジャンプします。）
Regional AOIは、その地域のニーズを取り入れて設定された独自のAOIです。
Regional AOIの申請手順／スケジュール／審査委員会は、Global AOIと同じです。
日本の申請窓口はMSD株式会社となります。申請をご検討の場合は、お早めに問い合せ／資料請求
先へ申請資料をご請求ください。
以上

Download Report